Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
November 1, 2024 7:21 AM EDTLeerink Partners analyst David Risinger raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $58.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line: We revised our model post-3Q results and bumped our DCF-derived PT from $56 to $58 (we... More
